Individual InvestorsBB Biotech AG
ISIN-No.: CH0038389992
YTD: -19.18%
Active share: 77.10
Anzahl Positionen: 26
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Indexed performance (as at: 18.04.2025)
Share price: EUR 28.65 (17.04.2025)
NAV: EUR 33.60 (17.04.2025)
Rolling performance (18.04.2025)
| Share Price | NAV | Benchmark | |
| 17.04.2024 - 17.04.2025 | -29.61% | -19.54% | -8.34% |
| 17.04.2023 - 17.04.2024 | -11.98% | 5.79% | -0.61% |
| 14.04.2022 - 17.04.2023 | -15.40% | -9.94% | 0.69% |
| 14.04.2021 - 14.04.2022 | -7.50% | -9.61% | -0.80% |
Annualized performance (18.04.2025)
| Share Price | NAV | Benchmark | |
| 1 year | -29.61% | -19.54% | -8.34% |
| 3 years | -19.37% | -8.48% | -2.84% |
| 5 years | -8.84% | -3.01% | 0.17% |
| 10 years | -1.62% | -1.11% | 0.73% |
| Since Inception p.a. | 9.72% | 10.33% | 9.86% |
Cumulative performance (18.04.2025)
| Share Price | NAV | Benchmark | |
| 1M | -17.64% | -14.97% | -15.38% |
| YTD | -19.18% | -20.72% | -15.86% |
| 1 year | -29.61% | -19.54% | -8.34% |
| 3 years | -47.59% | -23.35% | -8.28% |
| 5 years | -37.06% | -14.19% | 0.86% |
| 10 years | -15.05% | -10.52% | 7.51% |
| Since Inception | 1'166.70% | 1'376.64% | 1'211.89% |
Annual performance
| Share Price | NAV | Benchmark | |
| 2024 | -14.08% | 1.71% | 6.30% |
| 2023 | -15.21% | -1.29% | 1.26% |
| 2022 | -19.00% | -6.72% | -4.46% |
| 2021 | 13.34% | -7.79% | 7.39% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | Bank Julius Bär AG |
| Fund Administrator | Bellevue Asset Management AG |
| Auditor | Deloitte AG |
| Launch date | 09.11.1993 |
| Year end closing | 31. Dec |
| Management Fee | 1.10% |
| ISIN number | CH0038389992 |
| Valor number | 3838999 |
| Bloomberg | BBZA GY Equity |
| WKN | A0NFN3 |
Legal Information
| Legal form | Incorporate company |
| SFDR category | Article 8 |
Key data (31.03.2025, base currency CHF)
| Beta | 1.32 |
| Volatility | 31.10 |
| Tracking error | 14.49 |
| Active share | 77.10 |
| Correlation | 0.91 |
| Sharpe ratio | -0.03 |
| Information ratio | -0.17 |
| Jensen's alpha | -3.09 |
| No. of positions | 26 |
Portfolio as at 31.12.2024
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
March was a challenging month stock performance wise for BB Biotech’s portfolio companies. The macro and political backdrop remained difficult with political and regulatory uncertainty. BB Biotech remains focused on investing in companies developing breakthrough medicines and we are seeing fundamental progress in most of the portfolio companies.
At BB Biotech´s annual general meeting on March 19, 2025, the shareholders approved all agenda items including the re-election of Dr. Thomas von Planta, Dr. Clive Meanwell, Laura Hamill, Dr. Pearl Huang, Camilla Soenderby and Prof. Dr. Mads Krogsgaard Thomsen. BB Biotech paid out the proposed dividend of CHF 1.80 per share.
We have highlighted some of the latest news from our portfolio companies below.
Arvinas (-60.3%, in USD) announced on March 11, disappointing results from its Phase III VERITAC-2 clinical trial in breast cancer of patients whose disease progressed following prior treatment CDK 4/6 inhibitors and endocrine therapy.
Incyte (-17.6%, in USD) announced on March 17, disappointing results from its Phase III STOP-HS clinical trial evaluating the safety and efficacy of povarcitinib in adult patients with moderate to severe hidradenitis suppurativa.
Alnylam (+9.4%, in USD) announced on March 20, the FDA approval of Amvuttra for the treatment of ATTR-CM in adults to reduce cardiovascular mortality, hospitalizations and urgent heart failure visits. The approval expands the indication of Amvuttra, which now becomes the first and only therapeutic, approved by the FDA for the treatment of ATTR-CM and hATTR-PN in adults. On March 28, the company announced together with its partner Sanofi the FDA approval of Qfitlia.
Wave Life Sciences (-23.6%, in USD) announced on March 26, positive data from the Phase II FORWARD-53 trial with WVE-N531 which is being tested for the treatment of boys with Duchenne muscular dystrophy.
Dokumente
Show moreShow less
